Glucagon Like Peptides in Diabetes - Creative Peptides

Glucagon-like peptide-1(7–36) amide (GLP-1), a peptide secreted from intestinal enteroendocrine L cells, control systemic blood glucose homeostasis in humans after a meal. Therapies based on the GLP-1 are novel treatment options for type 2 diabetes that act through a variety of complementary mechanisms. Unlike other diabetes drugs, the insulinotropic effect of GLP-1 is self-limiting, as it falls once the plasma glucose level is lowered to normal range, reducing the risk of hypoglycemia. In addition, GLP-1 regulates postprandial glucose elevation through several other mechanisms, including promoting insulin gene transcription, stimulating pancreatic β-cell proliferation and neogenesis, inhibiting β-cell apoptosis, and blocking glucagon release.It also prevents gastric emptying and induces satiety, leading to body weight decrease.

This is collected by Creative Peptides. 

This article duplicated from: Creative Peptides

No corresponding comment

You’ve spoken and we’ve listened! We are excited to announce that the same great knowledge platform that you have come use and love over the years will be going through a rebrand and an upgrade. We believe that all good things don’t come to an end, but only evolve to be better. WikiOmni will now officially be called Knowpia. Please make sure your access is now directed to KNOWPIA.COM from all of your devices. In an effort to enhance the overall user experience, over the course of the next few months you will see a new and improved design layout with value-added features and advancements in functionality. Through extensive research & development, we know you will be happy with the new direction that we are taking to continue our vision to assemble the world’s largest platform of knowledge contributors. We thank you for taking this incredible journey with us!